Comorbidities and Treatment Patterns in People With Myasthenia Gravis in Denmark, Finland and Sweden: A Population‐Based Observational Study
MG treatment was broadly similar across the three Nordic countries, while also reflecting nation-specific therapeutic guidelines. Many pwMG required multiple therapies, underscoring risks of long-term immunosuppression and highlighting the need for vigilant management and future research of safer strategies.
Authors
- Tero Ylisaukko‐oja
- Sari Atula (ORCID: https://orcid.org/0000-0003-1293-9325)
- Aino Vesikansa (ORCID: https://orcid.org/0000-0002-6386-9956)
- Fredrik Berggren (ORCID: https://orcid.org/0000-0002-2267-0086)
- Mari Savolainen
- Juha Mehtälä (ORCID: https://orcid.org/0000-0003-4088-8561)
- Didier Pitsi
- Karin Humle
- Riina‐Minna Väänänen
- Ingrid Schager
- Fredrik Piehl
- John Vissing
Institutions
- University of Copenhagen (DK)
- Statistics Sweden (SE)
- Karolinska University Hospital (SE)
- University of Helsinki (FI)
- Helsinki University Hospital (FI)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Karolinska Institutet (SE)
- Elektrobit (Finland) (FI)
- Universitetshospitalernes Center for Sundhedsfaglig Forskning (DK)
- UCB Pharma (Belgium) (BE)
Publication Details
- Journal
- Muscle & Nerve
- Published
- 2026-03-15
- DOI
- https://doi.org/10.1002/mus.70211
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00